Bio Medica Laboratories Unveils Audited Financial Results for Fiscal Year Ended March 31, 2026; Board Approves Shareholder Actions
Bio Medica Laboratories Limited (formerly Bio Medica Laboratories Private Limited) has announced its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company's Board of Directors reviewed and approved these outcomes during a meeting held on July 27, 2026.The company also confirmed that it will conduct a Postal Ballot via e-voting to secure approval from members for several critical corporate proposals. A cutoff date for determining membership eligibility to vote has been set as Friday, July 24, 2026.
Key Board Decisions and Corporate Proposals
During the meeting, the Board of Directors considered and approved:1. The audited standalone and consolidated financial results for the year ended March 31, 2026, accompanied by the Auditor's Report.
2. A declaration confirming that the Statutory Auditors issued an unmodified opinion on both sets of financial results.
3. Key items requiring member approval via Postal Ballot:
* Consideration and approval of a proposal for the sale or disinvestment of a subsidiary company.
* Approval to advance loans, provide guarantees, and/or offer security under Section 185 of the Companies Act, 2013.
* Approving an increase in the threshold for loans, guarantees, securities provision, and investments under Section 186 of the Companies Act, 2013.
* Approval of a Related Party Transaction, including a Material Related Party Transaction, as per Section 188 of the Companies Act, 2013.
Mrs. Vishakha Agrawal of M/s Vishakha Agrawal & Associates, practicing Company Secretaries, has been appointed to scrutinize the Postal Ballot in a fair and transparent manner.
Financial Performance Summary (March 31, 2026)
The audited financial statements indicate robust operations across the group, with both standalone and consolidated results reflecting significant turnover and profit generation for the period.The profitability metrics are detailed below:
| Metric | Standalone Results (₹ Lakhs) | Consolidated Results (₹ Lakhs) |
|---|---|---|
| Total Income (I + II) | 3,843.04 | 4,311.31 |
| Total Expenses | 2,273.63 | 2,685.89 |
| Profit Before Tax | 1,569.41 | 1,625.42 |
| Basic Earnings Per Share (EPS) | 12.71 | 12.95 |
Financial Position as of March 31, 2026
The company's financial stability is reflected in its balance sheet figures. The consolidated entity reported substantial assets and liabilities at the end of the fiscal year.A summary of the key financial positions:
| Particulars (Amount in ₹ Lakhs) | Standalone Results | Consolidated Results |
|---|---|---|
| Total Equity & Liabilities | 5,745.83 | 7,330.84 |
| Total Non-current Assets | 908.37 | 1,864.21 |
| Inventories (Current Assets) | 3,330.55 | 3,636.84 |
| Long Term Borrowings | 1,625.81 | 3,155.62 |
The balance sheet summary is presented below:
| Particulars (in ₹ Lakhs) | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| I. Equity and Liabilities | ||
| Share Capital | 918.00 | 918.00 |
| Reserves and Surplus | 1,733.36 | 555.30 |
| Non-current Liabilities (Total) | 3,378.68 | 1,071.07 |
| Current Liabilities (Total) | 1,918.20 | 1,325.75 |
| TOTAL | 7,330.84 | 3,870.13 |
Cash Flow Highlights
The company's cash flow activities demonstrate varied streams across operations, investing, and financing for the year ended March 31, 2026.| Activity | Standalone Results (₹ Lakhs) | Consolidated Results (₹ Lakhs) |
|---|---|---|
| Net Cash Flow from Operating Activities (A) | -577.39 | -603.46 |
| Net Cash used in Investing Activities (B) | -18.52 | -211.00 |
| Net Cash used in Financing Activities (C) | 597.88 | 823.47 |
| Net Increase / (Decrease) in Cash & Cash Equivalents | 1.97 | 8.52 |
The audit reports for both the standalone and consolidated financial results confirmed that they were prepared in accordance with relevant accounting standards, and the statutory auditors issued an unmodified opinion on the results.
BMLL Stock Price Movement
On Monday, Bio Medica Laboratories Limited shares edged higher to settle at ₹141.45, marking a gain of 2.05%. The stock traded within a narrow band throughout the session, reaching a high of ₹141.55 against a daily volume of 21,000 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.